Lupin up 1.5% on deal with Italian firm

DALAL STREET SPIKES

Lupin gained 1.51 per cent to Rs 1,196 on signing a licensing agreement with ItalFarmaco, an Italian pharmaceutical company.

Lupin informed that the company signed an in-licensing agreement with ItalFarmaco, a leading Italian pharmaceutical company.

As per the agreement, the company would exclusively market their cardiovascular critical care product, Enoxaparin Sodium Injection, in pre-filled syringes under the brand name `Lupenox` in the Indian market.

Earlier in March 2006, Lupin's wholly-owned subsidiary, Lupin pharmaceuticals, entered into an agreement with Chester Valley Pharmaceuticals, United States, to promote Atopiclair Nonsteroidal Cream to pediatricians.

In February, Lupin and Aspen Pharmacare Holdings of South Africa signed a memorandum of understanding to establish a 50:50 joint venture for the development, manufacture and global marketing (except US, South Africa & India Trade) of select anti-TB products.